A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis
This study will evaluate the effect of each dose of MK-3655 versus placebo on the percentage of individuals with NASH resolution without worsening of fibrosis after 52 weeks. The primary hypothesis